Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.1K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

751
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
751
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

621
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
621
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

615
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
615
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

849
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
849

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Applicability of ischemic heart disease clinical practice guidelines in low- and middle-income countries.

International journal of cardiology·2026
Same author

Erratum: Author Correction to "Vaccination in Patients With Cardiovascular Disease: A Case-based Approach and Contemporary Review [Canadian Journal of Cardiology Open. Volume 7, Issue 10 (2025), 1375-1388]".

CJC open·2026
Same author

Focal <sup>99</sup>ᵐTc-HMDP Myocardial Uptake in Acute Myocardial Infarction: Expected Findings Analogous to PYP Imaging.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2026
Same author

iCARDIO Alliance global implementation guidelines for the management of obesity 2025 focus on prevention and treatment of cardiometabolic disease.

American journal of preventive cardiology·2026
Same author

Prevalence and Predictors of High Inflammatory Risk in Heart Failure Subtypes: Findings From the Global POSEIDON Study.

European journal of heart failure·2026
Same author

Taking a second chance: Unlocking myocardial recovery after left ventricular assist device support.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same journal

An integrative approach to patient selection for mitral transcatheter edge-to-edge repair in secondary mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial.

Current opinion in cardiology·2026
Same journal

Advancements in wearable technology for heart failure patients.

Current opinion in cardiology·2026
Same journal

Minimally invasive approaches to coronary artery bypass grafting: techniques, current evidence, and future directions.

Current opinion in cardiology·2026
Same journal

Advances in artificial intelligence for the evaluation of mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Role of nutritional interventions to reduce cardiometabolic disease burden in the community.

Current opinion in cardiology·2026
See all related articles

Related Experiment Video

Updated: Jan 2, 2026

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

3.4K

Hyperkalemia in heart failure.

Kiran Sidhu1, Rohan Sanjanwala, Shelley Zieroth

  • 1Section of Cardiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.

Current Opinion in Cardiology
|December 14, 2019
PubMed
Summary
This summary is machine-generated.

New therapies, patiromer and sodium zirconium cyclosilicate (SZC), effectively manage hyperkalemia in heart failure patients. These treatments enable optimal use of renin-angiotensin-aldosterone (RAAS) inhibitors, improving patient outcomes.

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.9K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.8K

Related Experiment Videos

Last Updated: Jan 2, 2026

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

3.4K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.9K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.8K

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Hyperkalemia is common in heart failure patients, often linked to diabetes and chronic kidney disease.
  • Renin-angiotensin-aldosterone (RAAS) inhibitors are crucial for heart failure management but can exacerbate hyperkalemia.
  • Limited effective and tolerable treatments for hyperkalemia have hindered RAAS inhibitor therapy.

Purpose of the Study:

  • To review novel therapies for hyperkalemia in heart failure patients.
  • To evaluate the role of patiromer and sodium zirconium cyclosilicate (SZC) in managing hyperkalemia.
  • To discuss the impact of these new agents on RAAS inhibitor therapy.

Main Methods:

  • Review of clinical studies on patiromer and SZC in heart failure.
  • Analysis of efficacy in maintaining normokalemia and safety profiles.
  • Assessment of onset of action for acute hyperkalemia treatment.

Main Results:

  • Patiromer and SZC effectively maintain normal potassium levels in heart failure patients.
  • These agents offer improved side effect profiles compared to older potassium binders.
  • SZC demonstrates rapid action for acute hyperkalemia management.

Conclusions:

  • Patiromer and SZC are valuable additions to managing heart failure patients with hyperkalemia.
  • These therapies facilitate sustained use and dose optimization of RAAS inhibitors.
  • Improved hyperkalemia control allows for better guideline-directed medical therapy implementation.